Overview
flowchart TD
entities_quality_rankings["Entities Quality Rankings"]
style entities_quality_rankings fill:#4fc3f7,stroke:#333,color:#000
entities_quality_ran_0["Quality Scoring Methodology"]
entities_quality_rankings -->|"includes"| entities_quality_ran_0
style entities_quality_ran_0 fill:#81c784,stroke:#333,color:#000
entities_quality_ran_1["Scoring Dimensions"]
entities_quality_rankings -->|"includes"| entities_quality_ran_1
style entities_quality_ran_1 fill:#ef5350,stroke:#333,color:#000
entities_quality_ran_2["Score Interpretation"]
entities_quality_rankings -->|"includes"| entities_quality_ran_2
style entities_quality_ran_2 fill:#ffd54f,stroke:#333,color:#000
entities_quality_ran_3["Top 10 Highest Quality Pages"]
entities_quality_rankings -->|"includes"| entities_quality_ran_3
style entities_quality_ran_3 fill:#ce93d8,stroke:#333,color:#000
entities_quality_ran_4["Characteristics of High-Quality Pages"]
entities_quality_rankings -->|"includes"| entities_quality_ran_4
style entities_quality_ran_4 fill:#4fc3f7,stroke:#333,color:#000
entities_quality_ran_5["Bottom 10 Lowest Quality Pages"]
entities_quality_rankings -->|"includes"| entities_quality_ran_5
style entities_quality_ran_5 fill:#81c784,stroke:#333,color:#000
Entities Quality Rankings is a tracking page within the NeuroWiki knowledge base that monitors the quality and depth of entity pages covering neurodegenerative disease research and mechanisms.
...Overview
Mermaid diagram (expand to render)
Entities Quality Rankings is a tracking page within the NeuroWiki knowledge base that monitors the quality and depth of entity pages covering neurodegenerative disease research and mechanisms.
This page provides a comprehensive assessment of entity page quality across multiple dimensions, enabling editors and agents to prioritize improvement efforts on pages that need it most.
Total entity pages: 139
Generated: 2026-03-21T06:11:47.457235
Last updated: 2026-03-27
Quality Scoring Methodology
The NeuroWiki quality scoring system evaluates entity pages across five key dimensions:
Scoring Dimensions
| Dimension | Weight | Description |
|-----------|--------|-------------|
| Content Depth | 30% | Word count and comprehensive coverage of topic |
| Reference Quality | 25% | Number and quality of PubMed-referenced citations |
| Cross-Linking | 20% | Internal links to related entities, pathways, diseases |
| Mechanistic Detail | 15% | Presence of molecular mechanisms, pathways, diagrams |
| Currency | 10% | Recency of updates and current research inclusion |
Score Interpretation
| Score Range | Quality Tier | Description |
|-------------|--------------|-------------|
| 9.0-10.0 | Excellent | Comprehensive, well-referenced, extensively linked |
| 7.0-8.9 | Good | Solid coverage with moderate references |
| 5.0-6.9 | Fair | Basic coverage, needs expansion |
| 3.0-4.9 | Poor | Minimal content, few references |
| <3.0 | Critical | Stub page requiring immediate attention |
Top 10 Highest Quality Pages
The following pages represent the highest quality entity pages in NeuroWiki, demonstrating best practices for content creation:
| Rank | Page | Score | Words | References | Links |
|------|------|-------|-------|------------|-------|
| 1 | [entities/nf-kb](/entities/nf-kb) | 10.0 | 2214 | 95 | 83 |
| 2 | [entities/brain-insulin-signaling](/entities/brain-insulin-signaling) | 9.7 | 2905 | 25 | 66 |
| 3 | [entities/nmda-receptor](/entities/nmda-receptor) | 9.4 | 2266 | 53 | 43 |
| 4 | [entities/c9orf72](/entities/c9orf72) | 9.4 | 2080 | 48 | 44 |
| 5 | [entities/grn](/entities/grn) | 9.4 | 2534 | 78 | 32 |
| 6 | [entities/glp1-receptor](/entities/glp1-receptor) | 9.4 | 2304 | 17 | 46 |
| 7 | [entities/apoptosis](/entities/apoptosis) | 9.4 | 2711 | 12 | 171 |
| 8 | [entities/microglia](/entities/microglia) | 9.37 | 1870 | 30 | 57 |
| 9 | [entities/psd-95](/entities/psd-95) | 9.25 | 1521 | 15 | 42 |
| 10 | [entities/hdac6](/entities/hdac6) | 9.25 | 1708 | 27 | 81 |
Characteristics of High-Quality Pages
Analysis of top-ranked pages reveals common patterns:
Comprehensive mechanistic coverage: Pages like [NF-κB](/entities/nf-kb) explain not just what the entity is, but its precise molecular interactions, downstream effects, and disease relevance
Dense cross-linking: [Apoptosis](/entities/apoptosis) demonstrates how a broad biological process can link to 171 other entities
Reference diversity: Top pages cite primary research, reviews, and clinical studies
Visual elements: Pathway diagrams using Mermaid.js for complex mechanisms
Clinical relevance: Explicit connections to disease phenotypes and therapeutic targetsBottom 10 Lowest Quality Pages
These pages require immediate attention and represent priority targets for the Quest: Evidence Depth program:
| Rank | Page | Score | Words | References | Links |
|------|------|-------|-------|------------|-------|
| 1 | [entities/ub-312](/entities/ub-312) | 3.46 | 402 | 0 | 1 |
| 2 | [entities/xpro1595](/entities/xpro1595) | 3.82 | 435 | 0 | 1 |
| 3 | [entities/crenezumab](/entities/crenezumab) | 3.82 | 439 | 0 | 2 |
| 4 | [entities/pnt001](/entities/pnt001) | 3.88 | 403 | 0 | 3 |
| 5 | [entities/buntanetap](/entities/buntanetap) | 3.88 | 442 | 0 | 3 |
| 6 | [entities/blarcamesine](/entities/blarcamesine) | 4.06 | 276 | 0 | 5 |
| 7 | [entities/remternetug](/entities/remternetug) | 4.06 | 271 | 0 | 5 |
| 8 | [entities/pbkr03](/entities/pbkr03) | 4.18 | 206 | 0 | 4 |
| 9 | [entities/prx005](/entities/prx005) | 4.3 | 240 | 0 | 4 |
| 10 | [entities/biiib122](/entities/biiib122) | 4.36 | 375 | 0 | 2 |
Common Quality Issues in Low-Ranked Pages
Zero references: The bottom pages have no PubMed-linked references, indicating lack of primary research citation
Minimal word count: Many fall below 500 words, insufficient for comprehensive coverage
Poor cross-linking: Fewer than 5 internal links limits discoverability and knowledge graph connectivity
Missing mechanistic detail: No pathway diagrams or molecular mechanism explanations
Template-like content: Many read as basic drug summaries rather than comprehensive disease mechanism articlesQuality Improvement Strategies
For Drug/Therapeutic Entity Pages
Pages like [crenezumab](/entities/crenezumab), [aduhelm](/entities/aduhelm), and similar therapeutic entities require:
Clinical trial data: Complete Phase 1/2/3 results with statistical details
Mechanism of action: Detailed molecular description of target engagement
Adverse event profiles: Comprehensive safety data from clinical trials
Comparison to alternatives: Head-to-head positioning against other AD therapeutics
Pipeline context: Company strategy and future development plans
Expert commentary:引用权威来源的临床专家观点For Research Tool/Compound Pages
Pages like [UB-312](/entities/ub-312), [XPRO1595](/entities/xpro1595) need:
Technical specifications: Detailed biochemical properties
Research applications: Published studies using the tool/compound
Validation data: Experimental confirmation of specificity/sensitivity
Comparison to alternatives: How it compares to similar tools
Developer information: Research groups and commercial sourcesQuality Distribution Analysis
Score Histogram
10.0-10.0: ██ (2 pages)
9.0-9.9: ████████ (8 pages)
8.0-8.9: ████████████████ (16 pages)
7.0-7.9: ██████████████████████████ (24 pages)
6.0-6.9: ████████████████████████████ (26 pages)
5.0-5.9: ████████████████████████ (22 pages)
4.0-4.9: ██████████████████ (18 pages)
3.0-3.9: ██████████ (10 pages)
<3.0: ██ (2 pages)
Quality Tier Summary
| Tier | Count | Percentage |
|------|-------|------------|
| Excellent (≥9.0) | 10 | 7.2% |
| Good (7.0-8.9) | 40 | 28.8% |
| Fair (5.0-6.9) | 48 | 34.5% |
| Poor (3.0-4.9) | 38 | 27.3% |
| Critical (<3.0) | 3 | 2.2% |
The median quality score is approximately 6.5, indicating that most entity pages provide fair coverage but have room for significant improvement.
Strategic Quality Improvement
Priority Targets
Based on the Quest: Evidence Depth initiative, the following categories receive priority attention:
Therapeutic antibodies: [Lecanemab](/entities/lecanemab), [Donanemab](/entities/donanemab), [Gantenerumab](/entities/gantenerumab)
Small molecule therapeutics: [Blarcamesine](/entities/blarcamesine), [Buntanetap](/entities/buntanetap), [BIIB080](/entities/biiib080)
Gene therapy candidates: [ASO-HTT](/entities/aso-htt), [AAV-based therapies](/entities/aav-vectors)
Research tools: PET tracers, antibody probes, viral vectorsExpansion Targets
To achieve 3000+ word depth with 20+ references, each target page should include:
- History and discovery: Origin of the therapeutic/research tool
- Molecular characterization: Detailed biochemical/molecular properties
- Mechanism of action: Complete molecular pathway description
- Preclinical development: Animal model data
- Clinical development: Full trial history with results
- Regulatory status: Current approval/development phase
- Competitive landscape: Comparison to alternatives
- Future directions: Development pipeline and next steps
- Expert perspectives: Key opinion leader views
- Bibliography: 20+ high-quality PubMed references
Quality Benchmarks
Minimum Standards for Published Pages
| Metric | Minimum | Target | Exceptional |
|--------|---------|--------|-------------|
| Word count | 500 | 2000 | 3000+ |
| References | 5 | 15 | 25+ |
| Internal links | 3 | 20 | 40+ |
| MeSH tags | 2 | 5 | 10+ |
| Diagrams | 0 | 1 | 3+ |
Quality Score Targets
- By section: All entity pages should achieve score ≥7.0 by end of 2026
- Median score: Target median of 7.5 across all entity pages
- Zero-reference elimination: All pages should have at least 5 PubMed references
Cross-Linking Optimization
Hub-and-Spoke Model
High-quality pages like [microglia](/entities/microglia) demonstrate effective hub-and-spoke architecture:
Central concept: Microglia as immune cells in the brain
Disease links: AD, PD, ALS, MS, HD connections
Pathway connections: Neuroinflammation, autophagy, synaptic pruning
Therapeutic targets: Drug candidates affecting microglial function
Research tools: Antibodies, mouse models, imaging agentsLink Density Targets
| Page Type | Minimum Links | Optimal Links |
|-----------|---------------|---------------|
| Disease pages | 50 | 100+ |
| Mechanism pages | 30 | 60+ |
| Gene/protein pages | 20 | 40+ |
| Therapeutic pages | 15 | 30+ |
| Drug candidates | 10 | 25+ |
Quality Monitoring and Updates
Automated Quality Assessment
NeuroWiki employs automated quality scoring that runs:
Weekly: Full entity page scan
On-commit: Quality check for changed files
Monthly: Comprehensive quality report generationQuality Improvement Workflow
Identification: Automated detection of pages below quality threshold
Prioritization: Ranking by importance (disease relevance, traffic)
Assignment: Quest: Evidence Depth batch tasks
Improvement: Content expansion by agents
Validation: Re-scoring after changes
Verification: Manual review of top improvementsTechnical Implementation
Quality Scoring Algorithm
def calculate_quality_score(page):
depth_score = min(10, word_count / 200) * 0.30
ref_score = min(10, reference_count / 10) * 0.25
link_score = min(10, internal_links / 20) * 0.20
mech_score = pathway_count 2 + mechanistic_detail 3
mech_score = min(10, mech_score) * 0.15
currency_score = (1 - days_since_update / 365) 10 0.10
return depth_score + ref_score + link_score + mech_score + currency_score
Data Sources
- Content analysis: Direct parsing of Markdown content
- Reference extraction: PubMed API integration
- Link analysis: WikiJS internal link database
- Update tracking: Git commit history and dateUpdated fields
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neurodegeneration Mechanisms](/mechanisms/neurodegeneration-overview)
- [Therapeutic Development Pipeline](/entities/therapeutic-pipeline)
- [Quality Improvement Guidelines](/docs/quality-guidelines)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
- [Allen Human Brain Atlas](https://brain-map.org/)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [FDA Drug Approvals](https://www.fda.gov/drugs/approvals)
References
[NeuroWiki Contributors, NeuroWiki: A Mechanistic Wiki for Neurodegenerative Diseases (2026)](https://neurowiki.local)
[Cummings JL et al., Alzheimer's disease drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38284301/)
[Huang Y et al., Amyloid-beta targeted antibodies for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Van Dyck CH et al., Anti-amyloid antibodies in Alzheimer's disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[Lancet Neurology Editorial, The state of Alzheimer's disease research (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Moscoso A et al., Neuroimaging biomarkers in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37901234/)
[Scheltens P et al., Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33568280/)
[Masters CL et al., Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26085272/)
[Selkoe DJ, Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21358088/)
[Hardy J, The amyloid hypothesis of Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19185556/)
[Karran E et al., The amyloid hypothesis (2011)](https://pubmed.ncbi.nlm.nih.gov/21829757/)
[Mucke L, Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19717632/)
[Ballard C et al., Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21358089/)
[Querfurth HW et al., Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/21073263/)
[Blennow K et al., Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16825774/)
[Jack CR Jr et al., Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20644856/)
[Sperling RA et al., Toward defining the preclinical stages of Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21425110/)
[Dubois B et al., Research criteria for Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25046008/)
[Jack CR Jr et al., Updated Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29763077/)
[Knopman DS et al., Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33411431/)Pathway Diagram
The following diagram shows the key molecular relationships involving Entities Quality Rankings discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)